Jan. 03, 2026 10:00 AM ETViking Therapeutics, Inc. (VKTX) StockLLY, NVO, PFE, LLY:CA, NONOF, NOVO:CA, NVON:CA, PFE:CA, ZLLY:CA, ZPFE:CAJR ResearchInvesting Group LeaderCommentsSummaryViking Therapeutics remains a compelling obesity drugs contender, despite being in the pre-commercial phase.VKTX's dual-track pipeline (injectable and oral) and robust $700M liquidity position it well to enter the obesity drugs gold rush.Phase III results for VK2735 are critical in 2026 for VKTX's commercialization prospects and potential market share gains.Maintaining a Buy rating on VKTX, bolstered by improving sentiments on the recovering healthcare sector and supported by ongoing optimism on its Phase III readouts.Looking for a helping hand in the market? Members of Ultimate Growth Investing get exclusive ideas and guidance to navigate any climate.